Cable Hill Partners’s Heron Therapeutics HRTX Stock Holding History

Cable Hill Partners’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-508	Closed	-$12K	–	375
2019 Q1	$12K	Buy	508 +400	+370%	+$10.5K	﹤0.01%	456
2018 Q4	$3K	Hold	108	–	–	﹤0.01%	662
2018 Q3	$3K	Sell	108 -219	-67%	-$8.16K	﹤0.01%	659
2018 Q2	$13K	Sell	327 -300	-48%	-$9.55K	0.01%	415
2018 Q1	$17K	Buy	627 +127	+25%	+$2.88K	0.01%	381
2017 Q4	$9K	Hold	500	–	–	﹤0.01%	597
2017 Q3	$8K	Buy	+500	New	+$7.84K	﹤0.01%	640

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Cable Hill Partners's HRTX Position: Q2 2019 in Review

Cable Hill Partners sold out of Heron Therapeutics (HRTX) in Q2 2019, closing a stake of 508 shares — an estimated $12K sold.

Cable Hill Partners first reported a position in HRTX in Q3 2017 and held it in 7 quarters. The position peaked at $17K in Q1 2018. 176 funds tracked by Wall St. Rank hold HRTX as of Q2 2019.

Cable Hill Partners reported no remaining Heron Therapeutics position as of Q2 2019 after selling out during the quarter.
Cable Hill Partners sold 508 Heron Therapeutics shares in Q2 2019, an estimated $12K.
Cable Hill Partners first reported a position in Heron Therapeutics in Q3 2017 and held it in 7 quarters.
Cable Hill Partners's Heron Therapeutics position peaked at $17K in Q1 2018.
176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2019.

Based on Cable Hill Partners's 13F filing for Q2 2019, filed 6 Aug 2019.